GUCY2C and colitis: Abundant evidence supports the notion that the Gucy2C‐cGMP signaling axis counteracts intestinal epithelial damage and tumorigenesis[24] underscoring the potential of targeting endogenous Gucy2C and Gucy1A transmembrane proteins in the later stages of colitis therapy.